Explore Daewoong Pharmaceutical’s research capabilities at a glance.
Proprietary Stem Cell Platform Technology
Stem Cell Platform
(DW-MSC)
Overview
- As society enters an aging era, the incidence of organ damage (a condition in which internal organs fail to function properly or become severely impaired) and neurodegenerative diseases is increasing. Since these conditions cannot be treated by pharmaceuticals alone, the development of new therapeutics aimed at restoring tissue function is required.
- DW-MSC is highly competitive due to its potential for stem cell commercialization and integration with diverse technologies. Based on cell and gene technologies, it aims to develop globally competitive stem cell therapeutics through smart stem cell technology convergence that maximizes therapeutic efficacy.
Key Differentiators
- High Consistency
Therapeutics with uniform characteristics derived from a single donor cell source
Continuous production of cell therapies with consistent quality through the establishment of a cGMP-grade cell bank - Cell & Gene Therapy Platform
Proprietary culture technology completely eliminating feeder cells, serum, and animal-derived components
Enhanced efficacy through priming (stem cell pretreatment) and genetic modification - Mass Production Technology
2D and 3D culture platform technologies
Maintenance of identical cell characteristics through up to 20 passages - Open Collaboration
Joint collaborative development of therapeutics for rare intractable and degenerative diseases
Flexible and diverse business models available